Clinical Trial Inclusion of People with Disabilities
Cross-source consensus on Clinical Trial Inclusion of People with Disabilities from 1 sources and 7 claims.
1 sources · 7 claims
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- People with disabilities, representing approximately 16% of the global population, remain persistently underrepresented in clinical research including clinical trials. — Equitable inclusion of people with disabilities in clinical trials: a scoping review
- People with Down syndrome face a 90–100% risk of developing Alzheimer's disease after age 65, yet have been systematically excluded from Alzheimer's disease trials leading to FDA-approved treatments, making it impossible to evaluate drug safety or efficacy in this group. — Equitable inclusion of people with disabilities in clinical trials: a scoping review
- Exclusion operates in two forms: explicit exclusion through eligibility criteria and implicit exclusion through inaccessible study designs, procedures, and environments. — Equitable inclusion of people with disabilities in clinical trials: a scoping review
- Current guidance on disability inclusion in clinical trials remains voluntary and inconsistently applied, and enforceable standards are needed. — Equitable inclusion of people with disabilities in clinical trials: a scoping review
- Exclusion of people with disabilities from trials is often based on incorrect assumptions that impairment prevents participation, rather than on scientific justification. — Equitable inclusion of people with disabilities in clinical trials: a scoping review
- A targeted recruitment program for individuals with schizophrenia achieved approximately a 40% increase in participant enrollment, demonstrating that disability-inclusive clinical research is operationally achievable. — Equitable inclusion of people with disabilities in clinical trials: a scoping review
- Most people with disabilities are fully capable of participating in clinical trials when reasonable accommodations are made, and exclusions are frequently not scientifically justified. — Equitable inclusion of people with disabilities in clinical trials: a scoping review